Sr. Director, HCP Products & Experiences

Role SummaryThe Sr. Director, HCP Products leads the full clinician digital experience at Pfizer and acts as the mini-GM for all HCP-facing digital products, anchored by PfizerPro and Prime. This is a net-new, global senior leadership role within DPX, reporting to the VP, DPX, and is among the most critical hires in the function.The role carries end-to-end accountability for the clinician experience (core platform journeys, engagement, personalization, and loyalty) across Pfizer’s owned HCP surfaces and the third-party clinical channels where HCPs increasingly start. Beyond running today’s surfaces, this leader defines the ecosystem strategy for HCP products: the role each owned property plays, where the highest-value clinician experiences should live, and how Pfizer shows up coherently across surfaces it owns and surfaces it never will. As a global role, it ensures core HCP platforms serve clinicians across markets, working closely with International Ecosystem Strategy so the experience is not US-only by default. It combines product leadership with the strategic mandate to redefine what Pfizer’s HCP surfaces should become, at the rhythm and regulatory complexity specific to clinician audiences.This leader owns the HCP surface as a product, not a portfolio of projects. They set HCP experience standards in partnership with Design & UX leadership, serve as the core DPX partner to Pfizer Medical, drive new features and emerging surfaces in partnership with ZTO, and operate as a peer within the DPX leadership team.Key ResponsibilitiesHCP Ecosystem Strategy & Global ReachDefine the strategy for Pfizer’s HCP digital ecosystem: establish a clear value proposition and role for each surface, anchored by owned properties (PfizerPro, Prime) and extending to the third-party clinical platforms where HCPs increasingly begin.Determine which clinician experiences Pfizer has the right to win, where to invest, where to consolidate a currently fragmented HCP estate, and where to participate through partnership rather than ownership.Own the HCP product vision as a global mandate, ensuring core platforms are architected and prioritized to serve clinician needs across markets, not as a US surface extended after the fact.Partner closely with International Ecosystem Strategy to consolidate market needs into the core roadmap, balancing global consistency with local relevance and regulatory variation, so market-specific needs are weighed deliberately rather than handled as exceptions.Stay ahead of shifts in how clinicians seek information and make decisions, including AI-driven discovery, ensuring Pfizer’s HCP presence evolves with clinician behavior rather than lagging it.HCP Surface Ownership & Product LeadershipAct as mini-GM for all HCP-facing digital products, with full accountability for surface performance, roadmap prioritization, and experience quality across PfizerPro, Prime, and adjacent owned surfaces.Translate clinician insight and commercial priority directly into product definition and a prioritized investment plan, working with embedded PMs scoped by capability.Own the forward roadmap: what to build, what to retire, what to unify.Champion human-centered methods to map clinician journeys, surface friction points, and define the high-value actions and content that drive measurable engagement.Data-Driven Roadmap & OptimizationGround roadmap and investment decisions in evidence: clinician behavior, surface performance, and business outcome data, not stakeholder volume or precedent. Establish clear success metrics and KPIs for each surface and major initiative, and hold the roadmap accountable to them.Retain full optimization ownership for HCP, given the distinct rhythm and stakeholder set specific to clinician audiences, with the Optimization Manager self-standardizing methodology with the Consumer counterpart.Build a deep, continuous optimization practice: a structured experimentation roadmap, disciplined A/B and multivariate testing, and a culture where surface changes are validated against clinician behavior before they scale. Position the function as the natural home for AI-driven testing as it matures, raising velocity without lowering the evidentiary bar.Push for co-ownership of the measurement that underpins these decisions, partnering with Analytics to prove what works rather than only receive reporting after the fact.Clinician Experience & StandardsOwn the quality of the end-to-end clinician experience across core journeys, engagement, personalization, and loyalty/retention.Partner with Design & UX leadership to define and uphold the standards of HCP experience, governed centrally but executed in-channel through the embedded UX Director.Ensure the HCP experience feels coherent and credible wherever clinicians encounter Pfizer, across owned surfaces and third-party clinical platforms alike.Strategic Partnerships: Medical, Emerging Surfaces & DeliveryServe as the core DPX partner to Pfizer Medical, ensuring the commercial HCP experience and Medical’s clinician-facing experiences complement rather than duplicate each other as both organizations serve the same customers; coordinate on surface roles, journey hand-offs, and experience standards.Shape how Pfizer shows up across the clinical channels where HCPs increasingly begin (e.g. Doximity, OpenEvidence, medical knowledge platforms), defining experience standards and product integration in coordination with Media and partnership owners rather than owning media buying or the partner relationship.Partner with owners of Pfizer’s other HCP-facing channels (email marketing, social media, CFC etc.) to drive an aligned omnichannel HCP experience to coordinate journey orchestration, message harmony, influence experience standards rather than owning those channels.Partner with ZTO to incubate and graduate new features and next-generation HCP surfaces into the core product line.Run the HCP channel against an explicit run/improve/explore capacity split, and